Data for: Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation
There is evidence that genetic polymorphisms of the drug efflux transporter ABCB1 (MDR1) may modulate substance abuse in humans. Also, some genetic variants of cytochrome P450 enzymes CYP2A6 and CYP2B6 have been associated with nicotine dependence and the outcomes of cessation treatments. The aim of this study was to investigate effects of genetic polymorphisms of ABCB1, CYP2A6, CYP2B6 on nicotine dependence in a Turkish population. 130 smokers and 130 non-smokers were recruited. For this purpose, subjects were genotyped for ABCB1 rs1128503/rs2032582/rs1045642, CYP2A6*1A/*1B/*4/*9, and CYP2B6 rs2279343 genetic polymorphisms. Also, plasma nicotine and nicotine metabolite levels from smokers were measured. The frequency of ABCB1 1236TT-2677TT-3435TT haplotype was found significantly higher in non-smokers as compared to smokers. There was no association between ABCB1 genetic variants and the success of smoking cessation. Neither the severity of nicotine dependence nor smoking cessation rates were associated with genetic variants of CYP2A6 or CYP2B6. This study suggests for the first time in literature that an all variant haplotype of ABCB1 (1236TT-2677TT-3435TT) may be associated with protection against nicotine dependence.